Federal pharmacy benefit manager transparency reforms must contend with concentrated pharmaceutical markets that lack competitive conditions. Learnings from transparency will shape future drug pricing reforms.
Mary Gens, MPP
Advertisement
Articles by Mary Gens, MPP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug
2
As GLP-1 Costs Climb, Medicare Part D Plans Face a Reckoning
3
ACO-SWITCH to Evaluate Tafamidis-to-Acoramidis Switch in ATTR-CM
4
Framework Charts a 3-Stage Path to Catch Psoriatic Arthritis Early
5